CVS had another strong quarter surpassing Wall Street expectations as it continued to witness a robust demand for COVID-19 tests and vaccines, administered at its pharmacies and clinics. This demand might be slower in the latter half of 2021 but the Delta variant could be an important factor that could benefit the company. The company witnessed a double-digit growth in almost all its segments but Covid-related costs did weigh upon its Aetna health insurance unit. It is worth mentioning that CVS ....
